Patheon Appoints Michel Lagarde President

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016
Volume 11
Issue 6

Lagarde will be based out of the company’s Boston office and will lead Patheon’s global corporate and cross-enterprise operations.

On May 31, 2016, Patheon announced that it has appointed Michel Lagarde president of the company. Lagarde will be based out of the company’s Boston office and will lead global corporate and cross-enterprise operations. He will report to the Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy and oversee its business segments, sales and marketing, and quality functions.

Lagarde joins Patheon from JLL Partners, a middle market private equity firm. For the past eight years, he has been working with several of JLL’s portfolio companies, including Patheon, in the healthcare and pharma services sectors as managing director. He has served as a member of Patheon’s Board of Directors since 2011. As a result of his appointment, Lagarde has stepped down from his position on Patheon’s Board of Directors.

Source: Patheon

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content